{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:03:04Z","timestamp":1790726584011,"version":"4.1.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Radiotherapy (RT) combined with chemoimmunotherapy may have synergistic effects and improve treatment efficacy and survival in extensive-stage small cell lung cancer (ES-SCLC). However, its association with survival appears to be inconsistent across different metastatic patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with metastatic SCLC diagnosed between 2020 and 2023 were identified from the Surveillance, Epidemiology, and End Results database. Propensity score matching (PSM), Kaplan\u2013Meier analysis, and Cox regression were used to evaluate the association between RT and cancer-specific survival (CSS). Inverse probability of treatment weighting (IPTW) and overlap weighting were performed as sensitivity analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 4707 patients were included. Liver metastasis was the most common site-specific metastasis (44.1%), followed by bone (42.1%), brain (30.1%), and lung metastasis (16.1%). Multi-organ metastases without brain involvement were the most common metastatic pattern (21.2%), followed by other\/unspecified (16.0%) and multi-organ metastases with brain involvement (15.5%). After 1:1 PSM, additional RT was associated with higher CSS in the liver only (HR, 0.68; 95% CI, 0.51\u20130.91; P\u00a0=\u00a0.009), lung only (HR, 0.55; 95% CI, 0.38\u20130.80; P\u00a0=\u00a0.002), multi-organ without brain (HR, 0.77; 95% CI, 0.64\u20130.92; P\u00a0=\u00a0.005), and other\/unspecified cohorts (HR, 0.67; 95% CI, 0.54\u20130.82; P\u00a0&amp;lt;\u00a0.001). No significant association was observed in the bone only, brain only, or multi-organ with brain cohorts. IPTW and overlap weighting analyses yielded consistent results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the immunotherapy era, among patients with metastatic SCLC receiving first-line chemoimmunotherapy, the association between additional RT and CSS may vary across metastatic patterns.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyag168","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:27:48Z","timestamp":1789673268000},"source":"Crossref","is-referenced-by-count":0,"title":["Association of radiotherapy with survival across metastatic patterns in metastatic small cell lung cancer in the immunotherapy era: a SEER analysis"],"prefix":"10.1093","author":[{"given":"Shulin","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Thoracic and Cardiovascular Surgery, The Second Affiliated Hospital of Chongqing Medical University , 76 Linjiang Road, Yuzhong District, Chongqing, 400010 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiang","family":"Bo","sequence":"additional","affiliation":[{"name":"Department of Thoracic and Cardiovascular Surgery, The Second Affiliated Hospital of Chongqing Medical University , 76 Linjiang Road, Yuzhong District, Chongqing, 400010 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology , Chongqing University Affiliated Renji Hospital (The Fifth People's Hospital of Chongqing), No. 121 Wangxi Road, Nan'an District, Chongqing 400062,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu","family":"Gao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Trauma and Chemical Poisoning, Department of Trauma Medical Center, Daping Hospital, Army Medical University, Changjiang Branch Road 10, Daping Street, Yuzhong District , Chongqing, 400042 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Thoracic and Cardiovascular Surgery, The Second Affiliated Hospital of Chongqing Medical University , 76 Linjiang Road, Yuzhong District, Chongqing, 400010 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1819-3181","authenticated-orcid":false,"given":"Cheng","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Thoracic and Cardiovascular Surgery, The Second Affiliated Hospital of Chongqing Medical University , 76 Linjiang Road, Yuzhong District, Chongqing, 400010 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"2026092919174045600_ref1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2026092919174045600_ref2","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up(\u2606)","volume":"32","author":"Dingemans","year":"2021","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology"},{"key":"2026092919174045600_ref3","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"2026092919174045600_ref4","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet (London, England)"},{"key":"2026092919174045600_ref5","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026092919174045600_ref6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026092919174045600_ref7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0140-6736(14)61085-0","article-title":"Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial","volume":"385","author":"Slotman","year":"2015","journal-title":"Lancet (London, England)"},{"key":"2026092919174045600_ref8","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.21037\/tlcr-23-294","article-title":"Safety and efficacy of thoracic radiotherapy combined with chemo-immunotherapy in patients with extensive-stage small cell lung cancer: a multicenter retrospective analysis","volume":"12","author":"Cai","year":"2023","journal-title":"TRANSL LUNG CANCER R"},{"key":"2026092919174045600_ref9","doi-asserted-by":"crossref","first-page":"1738352","DOI":"10.3389\/fimmu.2026.1738352","article-title":"Efficacy and safety of early radiotherapy combined with first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: a multi-center analysis","volume":"17","author":"Jia","year":"2026","journal-title":"Front Immunol"},{"key":"2026092919174045600_ref10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13014-024-02420-x","article-title":"Efficacy and safety of thoracic radiotherapy in extensive-stage small-cell lung cancer patients receiving first-line immunotherapy plus chemotherapy: a propensity score matched multicentre retrospective analysis","volume":"19","author":"Yao","year":"2024","journal-title":"Radiat Oncol"},{"key":"2026092919174045600_ref11","doi-asserted-by":"publisher","first-page":"102795","DOI":"10.1016\/j.eclinm.2024.102795","article-title":"Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line therapy for extensive-stage small-cell lung cancer (ES-SCLC): a phase II trial","volume":"75","author":"Chen","year":"2024","journal-title":"ECLINICALMEDICINE"},{"key":"2026092919174045600_ref12","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ijrobp.2025.06.3872","article-title":"Low-dose radiation therapy concurrent with atezolizumab and chemotherapy as first-line treatment for extensive-stage small cell lung cancer: 3-year follow-up of a Multicenter, single-arm, phase 2 trial (MATCH)","volume":"124","author":"Zhou","year":"2026","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026092919174045600_ref13","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2026.2330","article-title":"Consolidative thoracic radiotherapy with atezolizumab maintenance in extensive-stage small cell lung cancer: the phase 2 TREASURE randomized clinical trial (AIO-TRK-0320)","volume":"12","author":"Bozorgmehr","year":"2026","journal-title":"JAMA Oncol"},{"key":"2026092919174045600_ref14","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.2217\/fon-2017-0706","article-title":"The prognostic analysis of different metastatic patterns in extensive-stage small-cell lung cancer patients: a large population-based study","volume":"14","author":"Cai","year":"2018","journal-title":"Future Oncol"},{"key":"2026092919174045600_ref15","doi-asserted-by":"publisher","first-page":"111328","DOI":"10.1016\/j.radonc.2025.111328","article-title":"Consolidative thoracic radiotherapy in the immunotherapy era for extensive-stage small cell lung cancer: a systematic review and meta-analysis with emphasis on brain and liver metastases","volume":"216","author":"Wr\u00f3bel","year":"2026","journal-title":"Radiother Oncol"},{"key":"2026092919174045600_ref16","first-page":"1237","article-title":"Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer","volume":"5","author":"Wang","year":"2024","journal-title":"MED-CAMBRIDGE"},{"key":"2026092919174045600_ref17","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/s43018-022-00456-0","article-title":"Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect","volume":"3","author":"Nishiga","year":"2022","journal-title":"NAT CANCER"},{"key":"2026092919174045600_ref18","doi-asserted-by":"publisher","first-page":"215852","DOI":"10.1016\/j.canlet.2022.215852","article-title":"PARP inhibitor plus radiotherapy reshapes an inflamed tumor microenvironment that sensitizes small cell lung cancer to the anti-PD-1 immunotherapy","volume":"545","author":"Zhang","year":"2022","journal-title":"Cancer Lett"},{"key":"2026092919174045600_ref19","doi-asserted-by":"publisher","first-page":"110014","DOI":"10.1016\/j.radonc.2023.110014","article-title":"Chemoimmunotherapy combined with consolidative thoracic radiotherapy for extensive-stage small cell lung cancer: a systematic review and meta-analysis","volume":"190","author":"Feng","year":"2024","journal-title":"Radiother Oncol"},{"key":"2026092919174045600_ref20","doi-asserted-by":"publisher","first-page":"518","DOI":"10.3892\/ol.2025.15264","article-title":"Meta-analysis of the efficacy and safety of thoracic radiotherapy for extensive-stage small cell lung cancer in the era of immunotherapy","volume":"30","author":"Jiang","year":"2025","journal-title":"Oncol Lett"},{"key":"2026092919174045600_ref21","doi-asserted-by":"crossref","first-page":"17588359261477612","DOI":"10.1177\/17588359261477612","article-title":"Consolidative thoracic radiotherapy following first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: a systematic review and meta-analysis","volume":"18","author":"Canaslan","year":"2026","journal-title":"THER ADV MED ONCOL"},{"key":"2026092919174045600_ref22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s12672-023-00666-7","article-title":"Role of consolidative thoracic radiation in extensive-stage small-cell lung cancer with first-line chemoimmunotherapy: a retrospective study from a single cancer center","volume":"14","author":"Li","year":"2023","journal-title":"Discover oncology"},{"key":"2026092919174045600_ref23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13014-023-02308-2","article-title":"Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer","volume":"18","author":"Peng","year":"2023","journal-title":"Radiat Oncol"},{"key":"2026092919174045600_ref24","doi-asserted-by":"crossref","first-page":"e70175","DOI":"10.1002\/cam4.70175","article-title":"Impact of thoracic radiotherapy on first-line treatment outcomes in ES-SCLC patients","volume":"13","author":"Mu","year":"2024","journal-title":"CANCER MED-US"},{"key":"2026092919174045600_ref25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.21037\/tlcr-2026-1-0126","article-title":"Consolidative thoracic radiotherapy after first-line chemoimmunotherapy in extensive-stage small-cell lung cancer: a multicenter retrospective study","volume":"15","author":"Zhang","year":"2026","journal-title":"TRANSL LUNG CANCER R"},{"key":"2026092919174045600_ref26","doi-asserted-by":"publisher","first-page":"115592","DOI":"10.1016\/j.ejca.2025.115592","article-title":"Consolidation thoracic radiotherapy after chemoimmunotherapy in ES-SCLC: a multicentric retrospective analysis","volume":"225","author":"Monaca","year":"2025","journal-title":"Eur J Cancer"},{"key":"2026092919174045600_ref27","doi-asserted-by":"crossref","first-page":"e947713","DOI":"10.12659\/MSM.947713","article-title":"Thoracic radiation on survival in patients with advanced small cell lung cancer treated with chemoimmunotherapy","volume":"31","author":"Gao","year":"2025","journal-title":"MED SCI MONITOR"},{"key":"2026092919174045600_ref28","doi-asserted-by":"crossref","first-page":"17588359261444162","DOI":"10.1177\/17588359261444162","article-title":"Consolidation thoracic radiotherapy after chemoimmunotherapy provides survival benefit in elderly patients with extensive-stage small-cell lung cancer: a multicenter study","volume":"18","author":"Zhao","year":"2026","journal-title":"THER ADV MED ONCOL"},{"key":"2026092919174045600_ref29","doi-asserted-by":"crossref","first-page":"2542434","DOI":"10.1080\/07853890.2025.2542434","article-title":"Consolidative thoracic radiotherapy improves the prognosis of extensive stage small-cell lung cancer patients in the chemoimmunotherapy era: a multicenter retrospective analysis","volume":"57","author":"Yao","year":"2025","journal-title":"Ann Med"},{"key":"2026092919174045600_ref30","doi-asserted-by":"crossref","first-page":"1289434","DOI":"10.3389\/fimmu.2023.1289434","article-title":"Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in southern Italy","volume":"14","author":"Longo","year":"2024","journal-title":"Front Immunol"},{"key":"2026092919174045600_ref31","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1186\/s12885-025-15212-7","article-title":"Low-dose radiotherapy combined with chemoimmunotherapy yields superior survival outcomes compared with chemoimmunotherapy alone for patients with small cell lung cancer with liver metastasis: a retrospective study","volume":"25","author":"Zhang","year":"2025","journal-title":"BMC Cancer"},{"key":"2026092919174045600_ref32","doi-asserted-by":"publisher","first-page":"101114","DOI":"10.1016\/j.ctro.2026.101114","article-title":"Timing, fractionation, and dose of thoracic radiotherapy in patients with extensive-stage small cell lung cancer undergoing first-line chemo-immunotherapy","volume":"58","author":"Zhou","year":"2026","journal-title":"CLIN TRANSL RAD ONCO"},{"key":"2026092919174045600_ref33","doi-asserted-by":"crossref","first-page":"1175960","DOI":"10.3389\/fimmu.2023.1175960","article-title":"Hypofractionated radiotherapy with immunochemotherapy for extensive-stage small-cell lung cancer","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"2026092919174045600_ref34","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.21037\/tlcr-2024-1182","article-title":"Efficacy and safety of consolidative thoracic radiotherapy after first-line chemoimmunotherapy in patients with extensive-stage small-cell lung cancer: a retrospective cohort study","volume":"13","author":"Zheng","year":"2024","journal-title":"TRANSL LUNG CANCER R"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article-pdf\/doi\/10.1093\/jjco\/hyag168\/71469055\/hyag168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article-pdf\/doi\/10.1093\/jjco\/hyag168\/71469055\/hyag168.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:17:49Z","timestamp":1790723869000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article\/doi\/10.1093\/jjco\/hyag168\/8845815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":34,"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyag168","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"article-number":"hyag168"}}